Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

Abstract

Background:

Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis.

Objective:

To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials.

Methods:

Patients who were treatment naive (Comparison of Alemtuzumab and Rebif^® Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36).

Results:

Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS.

Conclusion:

Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL.

Keywords

Alemtuzumab CD52 antigen interferon beta-1a multiple sclerosis quality of life disease-modifying therapy

Get full access to this article

View all access options for this article.

References

Jones

Ford

Jones

et al . How people with multiple sclerosis rate their quality of life: An EQ-5D survey via the UK MS register. PLoS ONE 2013; 8: e65640.

Ruet

Deloire

Hamel

et al . Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: A 7-year longitudinal study. J Neurol 2013; 260: 776–784.

Confavreux

Vukusic

Moreau

et al . Relapses and progression of disability in multiple sclerosis. New Engl J Med 2000; 343: 1430–1438.

Klevan

Jacobsen

Aarseth

et al . Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurol Scand 2014; 129: 21–26.

Julian

Vella

Vollmer

et al . Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol 2008; 255: 1354–1360.

Flensner

Landtblom

Soderhamn

et al . Work capacity and health-related quality of life among individuals with multiple sclerosis reduced by fatigue: A cross-sectional study. BMC Public Health 2013; 13: 224.

Lobentanz

Asenbaum

Vass

et al . Factors influencing quality of life in multiple sclerosis patients: Disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004; 110: 6–13.

Miller

Rudick

Cutter

et al . Clinical significance of the multiple sclerosis functional composite: Relationship to patient-reported quality of life. Arch Neurol 2000; 57: 1319–1324.

Cella

Dineen

Arnason

et al . Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129–139.

10.

Yamout

Issa

Herlopian

et al . Predictors of quality of life among multiple sclerosis patients: A comprehensive analysis. Eur J Neurol 2013; 20: 756–764.

11.

Cohen

Coles

Arnold

et al . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380: 1819–1828.

12.

Coles

Twyman

Arnold

et al . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380: 1829–1839.

13.

Graves

Balcer

Palmer

et al . Alemtuzumab improves visual outcomes vs. subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis (RRMS) who relapsed on prior therapy: Analysis from the CARE-MS II study (I7–1.010). Neurology 2014; 82.

14.

Wray

Arnold

Cohen

et al . Alemtuzumab improves disability on MSFC and visual function in CARE-MS I. In: 4th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), San Diego, CA, 30 May–2 June 2012.

15.

Ware

Jr Sherbourne

. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.

16.

Johnston

Ebrahim

Carrasco-Labra

et al . Minimally important difference estimates and methods: A protocol. BMJ Open 2015; 5: e007953.

17.

Norman

Sloan

Wyrwich

. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003; 41: 582–592.

18.

Rudick

Miller

Hass

et al . Health-related quality of life in multiple sclerosis: Effects of natalizumab. Ann Neurol 2007; 62: 335–346.

19.

Brooks

. EuroQol: The current state of play. Health Policy 1996; 37: 53–72.

20.

Mallinckrodt

Clark

David

. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9–21.

21.

Mallinckrodt

Kaiser

Watkin

et al . The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 2004; 1: 477–489.

22.

Naci

Fleurence

Birt

et al . The impact of increasing neurological disability of multiple sclerosis on health utilities: A systematic review of the literature. J Med Econ 2010; 13: 78–89.

23.

Baumstarck

Pelletier

Butzkueven

et al . Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2013; 20: 907–914, e978–909.

24.

Benito-Leon

Mitchell

Rivera-Navarro

et al . Impaired health-related quality of life predicts progression of disability in multiple sclerosis. Eur J Neurol 2013; 20: 79–86.

25.

Drulovic

Riise

Nortvedt

et al . Self-rated physical health predicts change in disability in multiple sclerosis. Mult Scler 2008; 14: 999–1002.

26.

Patti

Pappalardo

Montanari

et al . Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: Results from a longitudinal study. J Neurol Sci 2014; 337: 180–185.

27.

Stephenson

Kern

Agarwal

et al . Impact of natalizumab on patient-reported outcomes in multiple sclerosis: A longitudinal study. Health Qual Life Out 2012; 10: 155.

28.

Crayton

Hunter

Huffman

et al . Improved quality of life after therapy change to fingolimod. In: 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Orlando, FL, 29 May–1 June 2013.

29.

Kita

Fox

Gold

et al . Effects of BG-12 (dimethyl fumarate) on quality of life in patients with relapsing–remitting multiple sclerosis (RRMS): An integrated analysis of the phase 3 DEFINE and CONFIRM studies (P07.092). Neurology 2013; 80.

30.

Montalban

Comi

O’Connor

et al . Oral fingolimod (FTY720) in relapsing multiple sclerosis: Impact on health-related quality of life in a phase II study. Mult Scler 2011; 17: 1341–1350.

31.

Baumstarck

Boyer

Boucekine

et al . Measuring the quality of life in patients with multiple sclerosis in clinical practice: A necessary challenge. Mult Scler Int 2013; 2013: 524894.

32.

Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.

33.

Coles

Compston

Selmaj

et al . Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801.

34.

Coles

Fox

Vladic

et al . Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78: 1069–1078.

35.

Fox

Arnold

Cohen

et al . Durable efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who participated in the CARE-MS studies: Three year follow-up (S41.001). Neurology 2013; 80.

36.

Gold

Rieckmann

Chang

et al . The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005; 12: 649–656.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB

0.23 MB

0.42 MB

0.23 MB